CRYGB

Across TCGA pan-cancer cohorts, CRYGB Mutation is linked to patient survival in 7 of 34 cancer types, making it a survival-associated CRYGB data layer compared with 16 for mass-spec protein.

The strongest signal is observed in esophageal carcinoma (ESCA), where higher CRYGB Mutation is associated with worse overall survival. In most high-consensus cancer types, elevated CRYGB expression acts as an unfavorable survival marker.

ESCA, KIRC, and BLCA are the cancer types where CRYGB Mutation most reproducibly stratifies survival.

Mutation survival associations by lineage

Ranked by sampling consensus. AUC1 and AUC2 indicate survival in the high- and low-expression groups, respectively; the lower AUC marks the poorer-surviving group. p-values are from the log-rank test.

Lineage	Measure	Split	Stage	AUC1 high	AUC2 low	p	Sampling consensus
ESCA	OS	Median	II,III,IV	0.074	0.703	<.001	48	view →
KIRC	OS	Median	All	0.129	0.806	<.001	21	view →
BLCA	OS	Median	All	0.177	0.609	.015	21	view →
LUAD	OS	Median	All	0.176	0.835	<.001	12	view →
PRAD	DFS	Median	All	0.085	0.774	<.001	6	view →
READ	OS	Median	All	0.281	0.823	.006	6	view →
LGG	OS	Median	All	0.307	0.811	.008	6	view →

Pink = unfavorable, green = favorable. Showing the 7 strongest of 7 lineages.

CRYGB–ESCA (OS)

Open the ESCA breakdown →